|
European patients need improved access to biosimilar medicines |
Medicines for Europe |
22 Apr 2021 |
Health & Consumers |
|
Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit |
Medicines for Europe |
28 Nov 2017 |
Health & Consumers, UK in Europe |
|
Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines |
Medicines for Europe |
05 Nov 2020 |
Health & Consumers |
|
Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market |
Medicines for Europe |
19 Sep 2016 |
Health & Consumers |
|
Future of pharmaceutical policy rests on secure supply of essential medicines |
Medicines for Europe |
03 May 2023 |
Health & Consumers |
|
Generic & biosimilar medicines pivotal for safe, effective and affordable access to medicines in Europe |
Medicines for Europe |
28 Nov 2019 |
Health & Consumers |
|
Generic medicine pricing reforms needed in Slovakia to ensure supply for patients |
Medicines for Europe |
23 Jun 2023 |
Health & Consumers |
|
Generic medicines: 70% of dispensed medicines and critical to healthcare |
Medicines for Europe |
10 Apr 2024 |
Health & Consumers |
|
Giving medicines a new life: EU should foster patients’ access to Value Added Medicines |
Medicines for Europe |
30 Nov 2022 |
Health & Consumers |
|
Harmonised bioequivalence guideline paves the way for global generic medicine development and access to medicines |
Medicines for Europe |
26 Apr 2023 |
Health & Consumers |
|
Health at a Glance Report highlights public value of generic, biosimilar and value added medicines |
Medicines for Europe |
26 Nov 2018 |
Health & Consumers |
|
HERA must address outstanding weaknesses in EU pharma framework to be successful |
Medicines for Europe |
16 Sep 2021 |
Health & Consumers |
|
IGBA congratulates the Australian Government for maintaining their Biologics Naming Convention and for strengthening pharmacovigilance |
Medicines for Europe |
29 Jan 2018 |
Health & Consumers |
|
IGBA launches a Biosimilar Medicines Information Campaign |
Medicines for Europe |
01 Feb 2018 |
Health & Consumers |
|
Immediately calls on new President of EU Commission to prioritise Healthcare |
Medicines for Europe |
25 Sep 2019 |
Health & Consumers, InfoSociety |
|
IQVIA Institute Scorecards show biosimilar medicines offer win for patients, policymakers and healthcare systems across Europe |
Medicines for Europe |
30 Jun 2020 |
Health & Consumers |
|
Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health |
Medicines for Europe |
16 Jun 2017 |
Health & Consumers |
|
Market reforms needed to secure essential antibiotics against AMR, report says |
Medicines for Europe |
16 Feb 2023 |
Health & Consumers |
|
Maximising the impact of Biosimilar Medicines requires strategic action in Europe |
Medicines for Europe |
05 Dec 2024 |
Health & Consumers |
|
Medicines for Europe announces new President, launches Access to Medicines campaign |
Medicines for Europe |
10 Oct 2017 |
Health & Consumers |
|
Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation |
Medicines for Europe |
22 Nov 2017 |
Health & Consumers |
|
Medicines for Europe can contribute much more to improve healthcare sustainability than described in the OECD “Health at a Glance 2016” report |
Medicines for Europe |
24 Nov 2016 |
Health & Consumers |
|
Medicines for Europe joins the Antimicrobial (AMR) One Health Network |
Medicines for Europe |
09 May 2023 |
Health & Consumers |
|
Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community |
Medicines for Europe |
22 Jun 2018 |
Health & Consumers |
|
Medicines for Europe statement on COVID-19 (‘coronavirus’) |
Medicines for Europe |
13 Mar 2020 |
Health & Consumers |
|
Medicines for Europe to join the ISPOR Issue Panel on value added medicines |
Medicines for Europe |
05 Oct 2017 |
Health & Consumers |
|
Medicines for Europe warns strongly against energy rationing for medicines production |
Medicines for Europe |
20 Jul 2022 |
Health & Consumers |
|
Medicines for Europe welcomes Competitiveness Council discussion to stop delocalisation of medicine manufacturing. It is time to effectively position Europe as a global hub for the production of medicines. |
Medicines for Europe |
30 Nov 2018 |
Health & Consumers |
|
Medicines for Europe, APOGEN and Fresenius Kabi hold Open Industry Day in Portugal |
Medicines for Europe |
14 Nov 2019 |
Health & Consumers |
|
New report assesses progress on biosimilar medicine policies across Europe |
Medicines for Europe |
30 Mar 2021 |
Health & Consumers |
